17 results
8-K
EX-99.1
ib27ph6 cupm
4 May 22
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
4:17pm
8-K
EX-99.1
o7zy 4rsd29
28 Mar 22
Jazz Pharmaceuticals Announces Agreement to Divest SunosiĀ® (solriamfetol) to Axsome Therapeutics
8:55am
8-K
EX-99.1
jb5mvtja
21 Dec 18
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive
8:18am
- Prev
- 1
- Next